Other Consolidated Financial Statement Detail

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:



	For the Three Months Ended June 30,						For the Six Months Ended June 30,
(In millions)	2015			2014			2015			2014
Interest income	$	4.3		$	2.4		$	7.6		$	5.1
Interest expense	(5.8		)	(7.1		)	(12.5		)	(14.7		)
Gain (loss) on investments, net	0.3			13.6			(1.4		)	16.6
Foreign exchange gains (losses), net	(1.5		)	(1.4		)	(14.5		)	(4.7		)
Other, net	(8.2		)	(2.6		)	(5.1		)	(3.0		)
Total other income (expense), net	$	(10.9	)	$	4.9		$	(25.9	)	$	(0.7	)

Other Current Assets

Other current assets includes prepaid taxes totaling approximately $280.5 million and $57.6 million as of June 30, 2015 and December 31, 2014, respectively.

Accrued Expenses and Other

Accrued expenses and other consists of the following:



(In millions)	As of June 30, 2015		As of December 31, 2014
Current portion of contingent consideration obligations	$	493.5	$	265.5
Revenue-related rebates	446.5		359.2
Employee compensation and benefits	214.4		393.8
Royalties and licensing fees	161.9		172.4
Deferred revenue	62.5		120.9
Other	433.3		507.5
Total accrued expenses and other	$	1,812.1	$	1,819.3

Other Long-Term Liabilities

Other long-term liabilities consist of the following:



(In millions)	As of June 30, 2015		As of December 31, 2014
Contingent consideration obligations	$	302.2	$	200.0
Employee compensation and benefits	224.5		200.7
Other	389.0		249.4
Total other long-term liabilities	$	915.7	$	650.1

Pricing of TYSABRI in Italy - AIFA

In the fourth quarter of 2011, Biogen Italia SRL (formerly Biogen Idec Italia SRL), our Italian subsidiary, received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In December 2011, we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit is unenforceable. That appeal is pending.

In June 2014, AIFA approved a resolution, effective for a 24 month term, setting the price for TYSABRI in Italy. This resolution also eliminated the reimbursement limit from February 2013 going forward. As a result, in June 2014, we recognized $53.5 million of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. In October 2014, we proposed a settlement to resolve all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the period from mid-February 2009 through January 2013 for an aggregate lump sum repayment of EUR35.6 million. The settlement agreement was sent to the Avvocatura Generale dello Stata (Attorney General) for its opinion. In June 2015, the Attorney General chose not to approve the settlement. AIFA and Biogen Italia SRL continue to discuss a possible resolution for this period. We have approximately EUR75 million recorded as accrued expenses and deferred revenue included within our long-term liabilities within our condensed consolidated balance sheets for this matter.

For additional information relating to our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 4, Accounts Receivable to our consolidated financial statements included within our 2014 Form 10-K.